Spyre Therapeutics, Inc.
NASDAQ:SYREBiotechnology
+$1.21 today
- Market cap
- $9.27B
- Beta
- 3.06
- P/E (TTM)
- -171.1
- EPS (TTM)
- -$0.52
Volume 0.63M
Average 1.17M
Returns on capital
Spyre Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-21.7%
avg -78.6%
ROIC
-29.1%
avg -66.7%
ROA
-20.0%
avg -58.4%
Analysis
ROA is currently the strongest return metric at -20.0% versus its period average of -58.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Cameron Turtle DPHIL | Chief Executive Officer & Director | USD 1.15M | 36 | — | — |
Sheldon Sloan | Chief Medical Officer | USD 778.56K | 67 | 0 | <0.01% |
Scott L. Burrows | Chief Financial Officer | USD 758.8K | 49 | 79.76K | 0.13% |
Heidy Abreu King-Jones | Chief Legal Officer & Corporate Secretary | USD 758.8K | 43 | — | — |
Eric McIntyre | Senior Vice President of Finance & Investor Relations | — | — | — | — |
James Myers | Senior Vice President of Quality & Compliance | — | — | — | — |
Melissa Cooper | Senior Vice President of People | — | — | — | — |
Janet Gunzner-Toste | Senior Vice President of Operations | — | — | — | — |
Justin LaFountaine | Senior Vice President of Corporate Development | — | — | — | — |
Brian Connolly | Chief Technical Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 1, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
94
$441.93M
Net Transaction Value
−$441.93M
Net selling
Most Active
Turtle Cameron
38 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 1, 26Oct 1, 2026 | King-Jones Heidy Direct | Sell | $1.5M$1,500,261.75 |
| Oct 1, 26Oct 1, 2026 | Burrows Scott L Direct | Sell | $135.4K$135,405.00 |
| Oct 1, 26Oct 1, 2026 | Burrows Scott L Direct | Sell | $193K$193,032.00 |
| Oct 1, 26Oct 1, 2026 | Burrows Scott L Direct | Sell | $285.4K$285,449.45 |
| Oct 1, 26Oct 1, 2026 | Burrows Scott L Direct | Sell | $21.4K$21,427.53 |
| Oct 1, 26Oct 1, 2026 | King-Jones Heidy Direct | Sell | $35.7K$35,696.00 |
| Oct 1, 26Oct 1, 2026 | King-Jones Heidy Direct | Sell | $660.3K$660,277.80 |
| Oct 1, 26Oct 1, 2026 | King-Jones Heidy Direct | Sell | $194.7K$194,670.00 |
| Oct 1, 26Oct 1, 2026 | King-Jones Heidy Direct | Sell | $243K$242,996.00 |
| Oct 1, 26Oct 1, 2026 | Turtle Cameron Direct | Sell | $53.5K$53,484.00 |
1–10 of 94
Summary
Insiders reported 0 buys worth $0.00 and 94 sells worth $441.93M over the last 12 months. That adds up to net selling of $441.93M. Turtle Cameron was the most active insider with 38 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | N/A4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Spyre Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about SYRE's management, answered from reported figures.
Who manages SYRE?
Spyre Therapeutics, Inc. (SYRE) lists 10 active executives. The top listed executive is Eric McIntyre, Senior Vice President of Finance & Investor Relations.
Are SYRE insiders buying or selling?
Recent insider activity shows net selling of $369.19M.
Continue the stock analysis
Jump to another research area for this company.